Linna Wang, Baixiong Huang, Yaling Zeng, Jiujie Yang, Zhi Li, Jerome P L Ng, Xiongfei Xu, Lu Su, Xiaoyun Yun, Liqun Qu, Ruihong Chen, Weidan Luo, Yuping Wang, Chang Chen, Lijun Yang, Yuanqing Qu, Wei Zhang, Joyce Tsz Wai Chan, Xingxia Wang, Betty Yuen Kwan Law, Simon Wing Fai Mok, Sookja Kim Chung, Vincent Kam Wai Wong
Epalrestat, an aldose reductase inhibitor (ARI), has been clinically adopted in treating diabetic neuropathy in China and Japan. Apart from the involvement in diabetic complications, AR has been implicated in inflammation. Here, we seek to investigate the feasibility of clinically approved ARI, epalrestat, for the treatment of rheumatoid arthritis (RA). The mRNA level of AR was markedly upregulated in the peripheral blood mononuclear cells (PBMCs) of RA patients when compared to those of healthy donors. Besides, the disease activity of RA patients is positively correlated with AR expression...
2023: International Journal of Biological Sciences